B · Normal
[Dongcheng Pharmaceutical: The subsidiary passed the US FDA on-site inspection for the first time] On September 11th, Dongcheng Pharmaceutical (002675.SZ) announced that the company's controlled subsidiary Zhongtai Biotech underwent an on-site inspection by the US FDA from July 17 to 18, 2026. It recently received the inspection report and passed with NAI zero "483" defect. The scope of this inspection is the raw material of chondroitin sulfate sodium, which marks that its quality system is in line with international requirements, which will help expand the international market and enhance core competitiveness.
Comments